A Pilot Study Combining a GC-Sensor Device with a Statistical Model for the Identification of Bladder Cancer from Urine Headspace

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Khalid, Tanzeela ^a   White, Paul ^b   De Lacy Costello, Ben ^b   Persad, Raj ^c   Ewen, Richard ^b   Johnson, Emmanuel ^a   Probert, Chris S ^a   Ratcliffe, Norman ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^c NORTH BRISTOL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VOLATILE ORGANIC COMPOUND;

ADULT; AGED; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; GAS CHROMATOGRAPHY; HUMAN; MALE; PREDICTIVE VALUE; SENSOR; STATISTICAL MODEL; TRANSITIONAL CELL CARCINOMA; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOSENSING TECHNIQUES; CASE-CONTROL STUDIES; CHROMATOGRAPHY, GAS; DISCRIMINANT ANALYSIS; HUMANS; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PILOT PROJECTS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84879931388     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069602     Document Type: Article

References (29)

1. Cancer Research UK (2012) Bladder cancer UK incidence statistics. Available: http://info.cancerresearchuk.org/cancerstats/types/bladder/incidence/uk-bladder-cancer-incidence-statistics. Accessed2 July 2 2012.
2. Kelly JD, Fawcett DP, Goldberg LC, (2009) Assessment and management of non-visible haematuria in primary care. BMJ 338: 227-232. doi:10.1136/bmj.b227. PubMed: 19151065.
3. Mostafid H, Persad R, Kockelbergh R, Fawcett D, (2010) Is it time to re-design the haematuria clinic? BJU Int 105: 585-588. doi:10.1111/j.1464-410X.2009.09108.x. PubMed: 20002672.
4. Rodgers M, Nixon J, Hempel S, Aho T, Kelly J, et al. (2006) Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess 10: I-6. PubMed: 16729917.
5. Jacobs BL, Montgomery JS, Zhang Y, Skolarus TA, Weizer AZ, et al. (2012) Disparities in bladder cancer. Urol Oncol 30: 81-88. doi:10.1016/j.urolonc.2011.08.011. PubMed: 22127016.
6. Gakis G, Kruck S, Stenzl A, (2010) Can the burden of follow-up in low-grade noninvasive bladder cancer be reduced by photodynamic diagnosis, perioperative instillations, imaging, and urine markers? Curr Opin Urol 20: 388-392. doi:10.1097/MOU.0b013e32833cc9f4. PubMed: 20657287.
7. Stenzl A, Hennenlotter J, Schilling D, (2008) Can we still afford bladder cancer? Curr Opin Urol 18: 488-492. doi:10.1097/MOU.0b013e32830b8925. PubMed: 18670272.
8. Babjuk M, Oosterlinc W, Sylvester R, Kaasinen E, Böhle A, et al. (2011) EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 59: 997-1008. doi:10.1016/j.eururo.2011.03.017. PubMed: 21458150.
9. Abogunrin F, O'Kane HF, Ruddock MW, Stevenson M, Reid CN, et al. (2012) The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. Cancer 118: 2641-2650. doi:10.1002/cncr.26544. PubMed: 21918968.
10. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, et al. (2005) Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66 (Suppl 1) (6: 35-63. doi:10.1016/j.urology.2005.08.064. PubMed: 16399415.
11. Noyes K, Singer EA, Messing EM, (2008) Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors. Curr Opin Urol 18: 533-539. doi:10.1097/MOU.0b013e32830b8910. PubMed: 18670280.
12. Spanel P, Smith D, Holland TA, Al Singary W, Elder JB, (1999) Analysis of formaldehyde in the headspace of urine from bladder and prostate cancer patients using selected ion flow tube mass spectrometry. Rapid Commun Mass Spectrom 13: 1354-1359. doi:10.1002/(SICI)1097-0231(19990730)13:14. PubMed: 10407324.
13. Willis CM, Church SM, Guest CM, Cook WA, McCarthy N, et al. (2004) Olfactory detection of human bladder cancer by dogs: proof of principle study. BMJ 329: 712. doi:10.1136/bmj.329.7468.712. PubMed: 15388612.
14. Willis C, Britton LE, Harris R, Wallace J, Guest CM, (2011) Volatile organic compounds as biomarkers of bladder cancer: Sensitivity and specificity using trained sniffer dogs. Cancer Biomarkers 8: 145-153.
15. Weber CM, Cauchi M, Patel M, Bessant C, Turner C, et al. (2011) Evaluation of a gas sensor array and pattern recognition for the identification of bladder cancer from urine headspace. Analyst 136: 359-364. doi:10.1039/c0an00382d. PubMed: 20967397.
16. Smith S, Burden H, Persad R, Whittington K, de Lacy Costello B, et al. (2008) A comparative study of the analysis of human urine headspace using gas chromatography-mass spectrometry. J Breath Res. doi:10.1088/1752-7155/2/3/037022.
17. De Lacy Costello BPJ, Ewen RJ, Ratcliffe NM, Sivanand PS, (2003) Thick film organic vapour sensors based on binary mixtures of metal oxides. Sens And Actuators B. 92: 159-166. doi:10.1016/S0925-4005(03)00258-2.
18. Barker M, Rayens W, (2003) Partial least squares for discrimination. J Chemom 17: 166-173. doi:10.1002/cem.785.
19. Smith S, White P, Redding J, Ratcliffe NM, Probert CSJ, (2010) Application of similarity coefficients to predict disease using volatile organic compounds. IEEE Sens J 10: 92-96. doi:10.1109/JSEN.2009.2035771.
20. Budman LI, Kassouf W, Steinberg JR, (2008) Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2: 212-221. PubMed: 18682775.
21. Software Vernier, and Technology (2013) Vernier Mini GC Plus Gas Chromatograph. Availablehttp://www.vernier.com/products/sensors/gc2-mini/. Accessed: 4 June 2013.
22. Zampolli S, Elmi I, Stürmann J, Nicoletti S, Dori L, et al. (2005) Selectivity enhancement of metal oxide gas sensors using a micromachined gas chromatographic column. Sens And Actuators B Chem 105: 400-406. doi:10.1016/j.snb.2004.06.036.
23. Agah M, Lambertus GR, Sacks R, Wise K, (2006) High-Speed MEMS-Based Gas Chromatography. J Microelectromechanical Syst 15: 1371-1378. doi:10.1109/JMEMS.2006.879708.
24. Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, et al. (2007) Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomarkers 3: 95-109.
25. Phillips M, Cataneo RN, Saunders C, Hope P, Schmitt P, Wai J, (2010) Volatile biomarkers in the breath of women with breast cancer. J Breath Res 4: 026003. doi:10.1088/1752-7155/4/2/026003. PubMed: 21383471.
26. McKay JA, Melvin WT, Ah-See AK, (1995) Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Lett 54: 270-272. PubMed: 7589551.
27. Carnell DM, Smith RE, Daley FM, et al. (2004) Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int J Radiat Oncol Biol Phys 58: 500-509. doi:10.1016/j.ijrobp.2003.09.064. PubMed: 14751521.
28. Roos PH, Bolt HM, (2005) Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opin Drug Metab Toxicol 1: 187-202. doi:10.1517/17425255.1.2.187. PubMed: 16922636.
29. Angelo J Sr, (2001) Dysfunctional mitochondria, not oxygen insufficiency, cause cancer cells to produce inordinate amounts of lactic acid: the impact of this on the treatment of cancer. Med Hypotheses 57: 429-431. doi:10.1054/mehy.2001.1335. PubMed: 11601863.